Introduction: There is a critical need to develop effective new strategies for the management of patients with advanced or recurrent endometrial cancer (EC) and molecular targeted therapies; in particular, antiangiogenic drugs represent an interesting field of pharmacological research. One of the most interesting of these agents is bevacizumab, a monoclonal antivascular endothelial growth factor antibody.
Areas Covered: Mechanism of action and clinical trials of bevacizumab in EC, and suggestions for its future use are reviewed. The most relevant papers and the meeting abstracts published up to December 2011 were used as sources for this review. The purposes of this manuscript are to discuss the rationale of interfering with the process of tumor angiogenesis in EC, to help readers in understanding the mechanism of action of bevacizumab, and to provide a comprehensive summary of initial preclinical and clinical results of this drug in EC patients.
Expert Opinion: Recent advances in the understanding of the molecular biology of EC have led to development of targeted therapies. Among these, antiangiogenic agents are one of the most promising therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14712598.2012.672558 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic values of molecular subtypes and SWI/SNF protein expression in de-differentiated/undifferentiated endometrial carcinoma.
Histopathology
January 2025
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Aims: Classification and risk stratification of endometrial carcinoma (EC) has transitioned from histopathological features to molecular classification, e.g. the ProMisE classifier, identifying four prognostic subtypes: POLE mutant (POLEmut) with almost no recurrence or disease-specific death events, mismatch repair deficient (MMRd) and no specific molecular profile (NSMP), with intermediate outcome and p53 abnormal (p53abn) with poor outcomes.
View Article and Find Full Text PDFAttitudes, beliefs and preferences surrounding home-based exercise programs in endometrial cancer patients receiving treatment.
Gynecol Oncol Rep
February 2025
University of Iowa, Department of Psychological and Brain Sciences, Holden Comprehensive Cancer Center, G60 Psychological and Brain Sciences Building, 340 Iowa Ave, Iowa City, IA 52242, USA.
Background: Despite recommendations, exercise participation among endometrial cancer survivors remains low. Previous interventions focused on weight loss or in-person programs with limited reach. Regular exercise, regardless of weight change, reduces mortality risk and improves functionality.
View Article and Find Full Text PDFPatterns of Care in Adjuvant Radiation Therapy for Stage II Endometrioid Endometrial Adenocarcinoma: A National Cancer Database Analysis.
Adv Radiat Oncol
February 2025
Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Purpose: Treating stage II endometrial cancer involves total hysterectomy, bilateral salpingo-oophorectomy, and risk-adapted adjuvant therapy. Professional guidelines support various adjuvant treatments, but high-level data supporting specific options are conflicting. We sought to evaluate adjuvant radiation therapy (RT) trends for these patients, hypothesizing increased utilization of pelvic external beam RT (EBRT) over time.
View Article and Find Full Text PDFGut microbiota and endometrial cancer: research progress on the pathogenesis and application.
Ann Med
December 2025
Department of Gynecology, the First Affiliated Hospital of Harbin Medical University, Harbin, China.
As one of the three major malignant tumors in women, the morbidity of endometrial cancer is second only to that of cervical cancer and is increasing yearly. Its etiological mechanism is not clear, and the risk factors are numerous and common and are closely related to obesity, hypertension, diabetes, etc. The gut microbiota has many strains, which play a considerable part in normal digestion and absorption in the human body and the regulation of the immune response.
View Article and Find Full Text PDFBurden of cancer attributable to sedentary behaviour in Germany: an epidemiological analysis of survey data.
BMJ Open
January 2025
Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.
Objectives: Sedentary behaviour (SB) is associated with increased risks of breast, colorectal, endometrial, ovarian and rectal cancers. However, the number of cancer cases attributable to SB in Germany and the associated costs are unknown.
Setting: Numbers and proportions (population-attributable fractions, PAF) of new cancer cases attributable to SB with published risk estimates for Germany for the years 2024, 2030 and 2040.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!